Go ahead in US bolsters Glaxo
DRUGS giant GlaxoSmithKline is further bolstering its early-stage product pipeline after a deal with Concert Pharmaceutical of the US to license treatment for HIV and kidney disease.
The deal could be worth up to £600million to Concert in milestone and royalty payments as it continues its research into drugs based on deuterium that can improve the efficacy of medicines.
GlaxoSmithKline, which has been investing in boosting its early-stage product profile, has also had its acquisition of skincare company Stiefel approved by US regulators.